Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 5 (2008), Issue 7 (July)

  1. Autonomous Hedgehog signalling is undetectable in PC-3 prostate cancer cells.
    Biochem Biophys Res Commun, 373(1): 109-12. [Abstract] [Full-text]
  2. The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.
    Clin Cancer Res, 14(13): 4241-9. [Abstract] [Full-text]
  3. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
    Clin Cancer Res, 14(13): 4200-5. [Abstract] [Full-text]
  4. Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence.
    Clin Cancer Res, 14(13): 4111-8. [Abstract] [Full-text]
  5. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.
    Cancer Res, 68(13): 5469-77. [Abstract] [Full-text]
  6. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression.
    Cancer Res, 68(13): 5460-8. [Abstract] [Full-text]
  7. Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics.
    Br J Cancer, 99(1): 78-82. [Abstract] [Full-text]
  8. Multiple loci with different cancer specificities within the 8q24 gene desert.
    J Natl Cancer Inst, 100(13): 962-6. [Abstract] [Full-text]
  9. Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study.
    Br J Cancer, 99(1): 176-8. [Abstract] [Full-text]
  10. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
    Am J Surg Pathol, 32(7): 1060-7. [Abstract] [Full-text]
  11. Management of acquired rectourinary fistulas: how often and when is permanent fecal or urinary diversion necessary?
    Dis Colon Rectum, 51(7): 1049-54. [Abstract] [Full-text]
  12. Cyclic adenosine monophosphate differentiated beta-endorphin neurons promote immune function and prevent prostate cancer growth.
    Proc Natl Acad Sci U S A, 105(26): 9105-10. [Abstract] [Full-text]
  13. Changes in baseline PSA levels in Japanese men from 1988 to 2003.
    Urology, 72(1): 95-8. [Abstract] [Full-text]
  14. Robotic prostatectomy: a review of outcomes compared with laparoscopic and open approaches.
    Urology, 72(1): 15-23. [Abstract] [Full-text]
  15. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.
    Urology, 72(1): 143-7. [Abstract] [Full-text]
  16. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
    Urology, 72(1): 167-71. [Abstract] [Full-text]
  17. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy.
    Urology, 72(1): 172-6. [Abstract] [Full-text]
  18. Indicators of sexual and somatic development and adolescent body size in relation to prostate cancer risk: results from a case-control study.
    Urology, 72(1): 183-7. [Abstract] [Full-text]
  19. Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years.
    Urology, 72(1): 177-82. [Abstract] [Full-text]
  20. Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.
    J Med Chem, 51(13): 3895-904. [Abstract] [Full-text]
  21. Survival following primary androgen deprivation therapy among men with localized prostate cancer.
    JAMA, 300(2): 173-81. [Abstract] [Full-text]
  22. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.
    BJU Int, 102(2): 253-8. [Abstract] [Full-text]
  23. Familial myeloma.
    N Engl J Med, 359(2): 152-7. [Abstract] [Full-text]
  24. Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer.
    Ann Diagn Pathol, 12(4): 260-6. [Abstract] [Full-text]
  25. Salvage prostate cryoablation: initial results from the cryo on-line data registry.
    J Urol, 180(2): 559-63; discussion 563-4. [Abstract] [Full-text]
  26. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.
    J Urol, 180(2): 565-70; discussion 570. [Abstract] [Full-text]
  27. Percent tumor involvement and risk of biochemical progression after radical prostatectomy.
    J Urol, 180(2): 571-6; discussion 576. [Abstract] [Full-text]
  28. Health risk behaviors and prostate specific antigen awareness among men in California.
    J Urol, 180(2): 658-62; discussion 662. [Abstract] [Full-text]
  29. Total prostate specific antigen stability confirmed after long-term storage of serum at -80C.
    J Urol, 180(2): 534-7; discussion 537-8. [Abstract] [Full-text]
  30. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
    J Urol, 180(2): 539-43; discussion 543. [Abstract] [Full-text]
  31. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry.
    J Urol, 180(2): 554-8. [Abstract] [Full-text]
  32. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies.
    J Urol, 180(2): 548-52; discussion 552-3. [Abstract] [Full-text]
  33. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer.
    J Urol, 180(2): 451-9; discussion 460. [Abstract] [Full-text]
  34. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.
    J Urol, 180(2): 544-7. [Abstract] [Full-text]
  35. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer.
    Br J Cancer, 99(2): 314-20. [Abstract] [Full-text]
  36. Rapid progression of prostate cancer in men with a BRCA2 mutation.
    Br J Cancer, 99(2): 371-4. [Abstract] [Full-text]
  37. Secular trends in mortality from common cancers in the United States by educational attainment, 1993-2001.
    J Natl Cancer Inst, 100(14): 1003-12. [Abstract] [Full-text]
  38. Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis.
    J Natl Cancer Inst, 100(14): 1022-36. [Abstract] [Full-text]
  39. Effects of DNAzymes targeting Aurora kinase A on the growth of human prostate cancer.
    Cancer Gene Ther, 15(8): 517-25. [Abstract] [Full-text]
  40. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis.
    Oncogene, 27(31): 4353-62. [Abstract] [Full-text]
  41. Extracellular redox state regulates features associated with prostate cancer cell invasion.
    Cancer Res, 68(14): 5820-6. [Abstract] [Full-text]
  42. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.
    Cancer Res, 68(14): 5785-94. [Abstract] [Full-text]
  43. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients.
    Cancer Res, 68(14): 5599-608. [Abstract] [Full-text]
  44. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner.
    Prostate, 68(12): 1319-29. [Abstract] [Full-text]
  45. Effects of antisense RNA targeting of ODC and AdoMetDC on the synthesis of polyamine synthesis and cell growth in prostate cancer cells using a prostatic androgen-dependent promoter in adenovirus.
    Prostate, 68(12): 1354-61. [Abstract] [Full-text]
  46. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity.
    Prostate, 68(12): 1283-95. [Abstract] [Full-text]
  47. Translationally regulated C/EBP beta isoform expression upregulates metastatic genes in hormone-independent prostate cancer cells.
    Prostate, 68(12): 1362-71. [Abstract] [Full-text]
  48. Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins.
    Prostate, 68(12): 1341-53. [Abstract] [Full-text]
  49. Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression.
    Prostate, 68(12): 1307-18. [Abstract] [Full-text]
  50. Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort.
    Prostate, 68(12): 1336-40. [Abstract] [Full-text]
  51. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations.
    Prostate, 68(12): 1257-62. [Abstract] [Full-text]
  52. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.
    BMC Med, 6: 19. [Abstract] [Full-text]
  53. Statin use and risk of prostate cancer: results from a population-based epidemiologic study.
    Am J Epidemiol, 168(3): 250-60. [Abstract] [Full-text]
  54. Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis.
    Radiology, 248(2): 531-9. [Abstract] [Full-text]
  55. Influence of organ motion on conformal vs. intensity-modulated pelvic radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 71(5): 1496-503. [Abstract] [Full-text]
  56. Comparison of combined x-ray radiography and magnetic resonance (XMR) imaging-versus computed tomography-based dosimetry for the evaluation of permanent prostate brachytherapy implants.
    Int J Radiat Oncol Biol Phys, 71(5): 1518-25. [Abstract] [Full-text]
  57. Image guidance based on prostate position for prostate cancer proton therapy.
    Int J Radiat Oncol Biol Phys, 71(5): 1322-8. [Abstract] [Full-text]
  58. In patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free interval.
    Int J Radiat Oncol Biol Phys, 71(5): 1295-301. [Abstract] [Full-text]
  59. Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10.
    Int J Radiat Oncol Biol Phys, 71(5): 1309-15. [Abstract] [Full-text]
  60. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 71(5): 1302-8. [Abstract] [Full-text]
  61. Salvage radiotherapy after postprostatectomy biochemical failure: does pretreatment radioimmunoscintigraphy help select patients with locally confined disease?
    Int J Radiat Oncol Biol Phys, 71(5): 1316-21. [Abstract] [Full-text]
  62. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.
    Biochem Biophys Res Commun, 373(3): 423-8. [Abstract] [Full-text]
  63. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis.
    Anesthesiology, 109(2): 180-7. [Abstract] [Full-text]
  64. Androgen deprivation by activating the liver X receptor.
    Endocrinology, 149(8): 3778-88. [Abstract] [Full-text]
  65. Expression and function of fatty acid amide hydrolase in prostate cancer.
    Int J Cancer, 123(6): 1318-26. [Abstract] [Full-text]
  66. Joint effects of inflammation and androgen metabolism on prostate cancer severity.
    Int J Cancer, 123(6): 1385-9. [Abstract] [Full-text]
  67. Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells.
    Int J Cancer, 123(6): 1255-61. [Abstract] [Full-text]
  68. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells.
    Oncogene, 27(32): 4422-33. [Abstract] [Full-text]
  69. Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials.
    Cancer Metastasis Rev, 27(3): 375-85. [Abstract] [Full-text]
  70. Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer.
    BMC Health Serv Res, 8: 146. [Abstract] [Full-text]
  71. Protein kinase D1 (PKD1) influences androgen receptor (AR) function in prostate cancer cells.
    Biochem Biophys Res Commun, 373(4): 618-23. [Abstract] [Full-text]
  72. No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
    Hum Mol Genet, 17(16): 2456-61. [Abstract] [Full-text]
  73. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.
    Cancer Immunol Immunother, 57(10): 1451-9. [Abstract] [Full-text]
  74. Association of HSP70-hom genetic variant with prostate cancer risk.
    Mol Biol Rep, 35(3): 459-64. [Abstract] [Full-text]
  75. Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development.
    J Clin Pathol, 61(8): 891-6. [Abstract] [Full-text]
  76. Selective amino acid restriction differentially affects the motility and directionality of DU145 and PC3 prostate cancer cells.
    J Cell Physiol, 217(1): 184-93. [Abstract] [Full-text]
  77. Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer.
    Br J Cancer, 99(3): 491-501. [Abstract] [Full-text]
  78. Positive surgical margins in areas of capsular incision in otherwise organ-confined disease at radical prostatectomy: histologic features and pitfalls.
    Am J Surg Pathol, 32(8): 1201-6. [Abstract] [Full-text]
  79. Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
    Oncogene, 27(33): 4569-79. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

American Cancer Society's Complete Guide to Prostate Cancer

American Cancer Society's Complete Guide to Prostate Cancer